Novo Nordisk ((DE:NOVA)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
In a recent clinical study update, Novo Nordisk is investigating the efficacy and safety of a new combination drug, CagriSema, for individuals with type 2 diabetes inadequately controlled on metformin, with or without an SGLT2 inhibitor. Officially titled ‘Efficacy and Safety of Co-administered Cagrilintide and Semaglutide (CagriSema) s.c. in Doses 2.4/2.4 mg and 1.0/1.0 mg Once Weekly Versus Semaglutide 2.4 mg and 1.0 mg, Cagrilintide 2.4 mg and Placebo in Participants With Type 2 Diabetes Inadequately Controlled on Metformin With or Without an SGLT2 Inhibitor,’ the study aims to evaluate how well CagriSema lowers blood sugar and body weight compared to its individual components and a placebo.
The intervention being tested is CagriSema, a combination of semaglutide and cagrilintide, administered as a weekly subcutaneous injection. This combination is intended to improve blood sugar control and promote weight loss in patients with type 2 diabetes.
The study is designed as an interventional, randomized, parallel assignment with quadruple masking (participant, care provider, investigator, outcomes assessor) to ensure unbiased results. The primary purpose of the study is treatment-focused, aiming to assess the therapeutic potential of CagriSema.
The study began on September 27, 2023, with an estimated primary completion date yet to be announced. The last update was submitted on July 15, 2025, indicating ongoing progress and adjustments in the study’s timeline.
This update could have significant market implications for Novo Nordisk, potentially boosting investor confidence and stock performance if CagriSema proves effective. The study’s outcome could also impact competitors in the diabetes treatment market, as successful results may set a new standard for combination therapies.
The study is currently active but not recruiting, with further details available on the ClinicalTrials portal.